NCT00834457 - A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

AIDS-related Kaposi's Sarcoma

Interventions

DRUG

abacavir/3TC/zidovudine

continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks

DRUG

abacavir /3TC plus ritonavir boosted lopinavir

fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks

Trial Locations (1)

University of Zimbabwe College of Health Sciences Department of Medicine, Harare